Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Darren Compas

Nurse Practitioner, Adult Health Bentonville, AR Nurse Practitioner

NPI 1871976738 CMS profile 10726413

609 Sw 8Th St, 6Th Floor, Bentonville, AR 72712

Open in the dashboard

General payments

$7,818

445 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Darren Compas of Bentonville, AR is reported in the CMS Open Payments database as having received $7,818 across 445 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $974 45
2024 General $1,695 88
2023 General $2,438 145
2022 General $1,468 92
2021 General $1,242 75

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Darren Compas
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Darren Compas were reported at $974. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Darren Compas Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,242 $138 $43–$438 $132
2022 $1,468 $165 $54–$494 $149
2023 $2,438 $178 $61–$549 $160
2024 $1,695 $186 $62–$575 $164
2025 $974 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,320 101 payments
  2. Otsuka America Pharmaceutical, Inc. $1,072 52 payments
  3. Janssen Pharmaceuticals, Inc $813 39 payments
  4. Neurocrine Biosciences, Inc. $739 36 payments
  5. Alkermes, Inc. $696 30 payments
  6. ITI, Inc. $630 37 payments
  7. Teva Pharmaceuticals USA, Inc. $529 39 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $442 27 payments
  9. Axsome Therapeutics, Inc. $416 20 payments
  10. Lundbeck LLC $386 19 payments
  11. Other $774 45 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,818 445 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,040 88 payments
  2. REXULTI $981 48 payments
  3. SPRAVATO $723 35 payments
  4. INGREZZA $710 34 payments
  5. CAPLYTA $575 34 payments
  6. ARISTADA Cns $497 20 payments
  7. ARISTADA Cns $497 20 payments
  8. TRINTELLIX $442 27 payments
  9. LYBALVI $441 22 payments
  10. ARISTADA Cns $429 17 payments
  11. Other $4,291 224 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,767

Median for Nurse Practitioner: 389

Drug cost

$291,240

Median for Nurse Practitioner: $21,885

Branded share of claims

17.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 24 $197,650
Vraylar Cariprazine Hcl Brand 11 $24,097
Rexulti Brexpiprazole Brand 16 $23,590
Mirtazapine Generic 159 $3,392
Fluvoxamine Maleate Generic 61 $2,982
Atomoxetine Hcl Generic 31 $2,521
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 19 $2,510
Duloxetine Hcl Generic 119 $2,340
Trazodone Hcl Generic 225 $2,172
Quetiapine Fumarate Generic 147 $2,041

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$47,757

Medicare's payments for the services billed

Medicare patients

106

Average age 68

Services billed

869

68 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 70%
Arthritis 60%
Diabetes 25%
COPD 24%
Ischemic heart disease 21%
Chronic kidney disease 19%
Alzheimer's or dementia 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $289
  • Lundbeck LLC $123
$412 16 —
VRAYLAR
  • AbbVie, Inc. $273
$273 11 —
CAPLYTA
  • ITI, Inc. $184
$184 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $159
$159 24 —
Auvelity
  • Axsome Therapeutics, Inc. $156
$156 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

445 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record